ERRATA

The April 1, 2007, article by Ruzzo et al, entitled “Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy” (J Clin Oncol 25:1247-1254, 2007), contained an error.

In the References section, reference 44 was given as: 44. Cunningham D, Norman AR, Chong G, et al: Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 16:1305-1310, 2005.

Whereas it should have been: 44. Negri FV, Wotherspoon A, Cunningham D, et al: Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 16:1305-1310, 2005.

DOI: 10.1200/JCO.2009.23.9228

The January 10, 2008, article by Kyriakou et al, entitled “High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome—Lymphoma Working Party of the European Group for Blood and Marrow Transplantation” (J Clin Oncol 26:218-224, 2008), contained an error in the online version. The DOI no. was given as 10.1200/JCO.2007.12.6219, and should have been 10.1200/JCO.2008.12.6219.

DOI: 10.1200/JCO.2009.23.6919

The March 10, 2009, article by Huo et al, entitled “Prediction of *BRCA* Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States” (J Clin Oncol 27:1184-1190, 2009), contained errors.

The following additional study support and disclaimers were inadvertently omitted:

Supported by National Cancer Institute, NIH, under RFA-CA-06-503, and through cooperative agreements with members of the Breast Cancer Family Registry, including Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), and Huntsman Cancer Institute (U01 CA69446). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the CFR.

DOI: 10.1200/JCO.2009.23.9244

The April 20, 2009, article by Galanis et al, entitled “Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study” (J Clin Oncol 27:2052-2058, 2009), contained errors.

In the Discussion section, the last sentences of the fourth and fifth paragraphs referred to the North American Brain Tumor Coalition, whereas it should have been the North American Brain Tumor Consortium.